European Celebration of 5 Years of Progress with CARB-X
A virtual discussion of progress and plans to accelerate innovation globally

22^nd of October, 2021, 3:30 – 4:30pm CET / 9:30 – 10:30am ET

Antibiotic-resistance undermines the safety net for modern medicine. Chemotherapy, surgeries, transplantation, childbirth – all of these and more depend on antibiotics to treat infection.  At least 700,000 people die each year due to antibiotic-resistant (AMR) infections, according to a recent WHO report. A recent Lancet publication from the European Center for Disease Prevention and Control (ECDC) estimates that approximately 33,000 deaths in the EU each year can be attributed to AMR, and an Organization of Economic Cooperation & Development OECD report calculates about 1.1 billion Euros are required for the health care systems of EU/EEA countries to address AMR.

CARB-X and its partners are taking action. CARB-X has funded 92 projects in 12 countries totaling more than $360 million since it launched in 2016. In Europe, the support of Wellcome Trust, the German Ministry of Health and Education, and the UK Global AMR Innovation Fund was critical to this progress over the past five years.

Today, the CARB-X portfolio is the world’s largest and most scientifically diverse antibacterial R&D portfolio. We are currently accelerating projects focused on the most serious antibiotic-resistant bacteria, including new classes of antibiotics and non-traditional agents, vaccines and other preventatives such as CRISPR-phage, microbiome-modifying agents and antibodies, and rapid diagnostics.

Please join us for a virtual discussion of the critical role that CARB-X and its global partners play in driving the development of innovative products to address the antibiotic-resistant bacteria health crisis.

CARB-X Executive Director Kevin Outterson will highlight achievements, especially in Europe and speak to CARB-X’s future vision and strategy.

European-based funders of CARB-X will outline their objectives and strategy in preparedness and how CARB-X delivery over 2016-2021 has met some of these goals.

Several European product developers in the current CARB-X portfolio will speak about their innovative products and their experience working with CARB-X.

A panel of experts will discuss antibiotics as the safety net for modern medicine and the challenges of bringing innovative products to patients in Europe.

• Veronika von Messling – Director-General for Life Sciences at the German Federal Ministry of Education and Research (confirmed)
• Florence Séjourné – Chief Executive Director of Da Volterra and President of BEAM Alliance (confirmed)
• Sir Jeremy Farrar – Director of Wellcome Trust & Member of the One Health Global Leaders Group on AMR (confirmed)
• Otto Cars – Founding Director of ReAct, Senior Professor, Infectious Diseases, Uppsala University, and former member of UN Inter-Agency Coordination Group on AMR (confirmed)

Click here to register, and to find out more about this important virtual meeting.